Hormones and Heart Disease: Estrogen, Testosterone, and Cardiovascular Protection
Heart disease is the leading cause of death for both men and women in the United States, yet the hormonal dimension of cardiovascular risk is rarely discussed in mainstream medical care. The evidence is substantial: estrogen is cardioprotective in women, testosterone plays an important role in men's cardiovascular health, and the hormonal shifts of aging contribute meaningfully to the increased cardiovascular risk of midlife and beyond.
Estrogen and the Cardiovascular System
Before menopause, women have significantly lower rates of cardiovascular disease than men of the same age. This "female advantage" is largely attributed to estrogen. After menopause, when estrogen levels fall, women's cardiovascular risk rises sharply and within a decade approximates that of men. This pattern is one of the most compelling pieces of evidence for estrogen's cardioprotective role.
Mechanistically, estrogen benefits the cardiovascular system in multiple ways. It promotes vasodilation through nitric oxide production, reducing arterial stiffness and resting blood pressure. It favorably affects the lipid profile — raising HDL ("good") cholesterol and lowering LDL ("bad") cholesterol — and reduces LDL oxidation, a key step in atherosclerotic plaque formation. Estrogen also reduces inflammatory cytokines, improves endothelial function (the health of the artery lining), and supports healthy blood glucose and insulin sensitivity, reducing metabolic risk factors for cardiovascular disease.
Estrogen receptors are expressed throughout the cardiovascular system — in the heart muscle, in arterial walls, and in vascular smooth muscle. This widespread receptor presence reflects estrogen's deep integration with cardiovascular physiology, not a peripheral relationship.
The Timing Hypothesis: When You Start Hormone Therapy Matters
One of the most important concepts in the BHRT and cardiovascular health discussion is the "timing hypothesis" or "window of opportunity." Early observational studies suggested a cardiovascular benefit to hormone therapy in women. The WHI trial, which enrolled mostly older postmenopausal women (average age 63, many of whom were more than 10 years past menopause), initially appeared to show no benefit and possibly harm. This discrepancy led to decades of controversy.
Subsequent re-analysis revealed that cardiovascular outcomes depended critically on when hormone therapy was initiated relative to menopause. Women who began hormone therapy within 10 years of menopause — particularly within the first 5 years — showed reduced cardiovascular events and mortality. Women who began therapy more than 10 years after menopause, who already had established subclinical atherosclerosis, showed no cardiovascular benefit and possibly increased risk.
The current consensus from major cardiovascular and endocrinology organizations is that BHRT initiated early in the menopausal transition, before significant vascular disease has developed, is likely cardioprotective. Waiting until midlife to address hormonal decline from a cardiovascular standpoint appears to forfeit much of the potential benefit.
Testosterone and Men's Cardiovascular Health
The relationship between testosterone and cardiovascular health in men has been subject to considerable debate, partly because early observational studies found associations between low testosterone and higher cardiovascular risk — suggesting that low T was a marker of poor health rather than a cause of it.
More recent evidence, including the large TRAVERSE trial (2023), provides important clarity. This randomized controlled trial found that testosterone therapy in men with hypogonadism and high cardiovascular risk did not increase major adverse cardiovascular events compared to placebo. While testosterone therapy slightly increased the incidence of atrial fibrillation and pulmonary embolism, it did not increase heart attack or stroke rates. For men with established symptomatic testosterone deficiency and appropriately managed hematocrit, testosterone therapy appears cardiovascularly safe in the context of appropriate monitoring.
Low testosterone in men is independently associated with increased visceral adiposity, insulin resistance, hypertension, dyslipidemia, and inflammation — all major cardiovascular risk factors. Correcting testosterone deficiency often improves these markers, which may explain why observational studies consistently associate higher testosterone levels with better cardiovascular outcomes in men.
Cardiovascular Risk Monitoring on BHRT
Appropriate monitoring is essential for patients on BHRT. Key cardiovascular markers to track include blood pressure, lipid panel, fasting glucose and insulin, C-reactive protein (a marker of systemic inflammation), and hematocrit (particularly in men on testosterone, as testosterone stimulates red blood cell production and elevated hematocrit increases clotting risk).
Route of estrogen delivery matters for cardiovascular safety. Oral estrogen undergoes first-pass liver metabolism, which can elevate clotting factors and triglycerides. Transdermal estradiol (patches, gels, creams) bypasses liver metabolism and does not carry the same clotting risk, making it the preferred route for women with any thrombotic risk factors.
Comprehensive Cardiovascular and Hormonal Health
Cardiovascular health and hormonal health are not separate domains — they are deeply intertwined. An optimized hormonal status supports a healthy cardiovascular system; a healthy lifestyle (regular exercise, anti-inflammatory nutrition, stress management, quality sleep) supports hormonal balance. The most effective approach to long-term cardiovascular health integrates both.
Kenton Bruice, M.D. takes a comprehensive, data-driven approach to hormonal health that includes careful attention to cardiovascular risk factors and markers. If you are concerned about your cardiovascular health in the context of hormonal changes, schedule a consultation at his Denver, Aspen, or St. Louis practice for a thorough evaluation and personalized plan.